16 Biotechnology Stocks to Sell Now

This week, the overall grades of 16 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a C to a D rating, Ionis Pharmaceuticals, Inc. (IONS) takes a hit this week. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of IONS stock.

Foundation Medicine, Inc. (FMI) gets weaker ratings this week as last week’s C drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FMI stock.

Achillion Pharmaceuticals, Inc. (ACHN) is having a tough week. The company’s rating falls from a C to a D. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Aegerion Pharmaceuticals, Inc. (AEGR) experiences a ratings drop this week, going from last week’s D to a F. Aegerion Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of AEGR stock.

Aldeyra Therapeutics, Inc. (ALDX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

Inovio Pharmaceuticals, Inc. (INO) earns a D this week, moving down from last week’s grade of C. Inovio Pharmaceuticals, Inc. engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of INO stock.

This is a rough week for Chemocentryx, Inc. (CCXI). The company’s rating falls to D from the previous week’s C. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

This week, ARCA biopharma, Inc.’s (ABIO) rating worsens to a D from the company’s C rating a week ago. ARCA biopharma, Inc. is a biopharmaceutical company whose main focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ABIO stock.

Agenus Inc.’s (AGEN) rating weakens this week, dropping to a D versus last week’s C. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

This week, Vericel Corporation (VCEL) drops from a C to a D rating. The company also gets F’s in earnings momentum and free cash flow. For more information, get Portfolio Grader’s complete analysis of VCEL stock.

VBI Vaccines Inc (VBIV) slips from a C to a D this week. For more information, get Portfolio Grader’s complete analysis of VBIV stock.

This week, Actinium Pharmaceuticals, Inc. (ATNM) drops from a C to a D rating. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ATNM stock.

This week, Conatus Pharmaceuticals Inc.’s (CNAT) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

Pieris Pharmaceuticals, Inc.’s (PIRS) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

Celator Pharmaceuticals, Inc. (CPXX) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CPXX stock.

This is a rough week for Celsion Corporation (CLSN). The company’s rating falls to D from the previous week’s C. Celsion Corporation is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLSN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/01/16-biotechnology-stocks-to-sell-now-4/.

©2021 InvestorPlace Media, LLC